Добро пожаловать
Нажатие «Авторизоваться» означает, что вы соглашаетесь с Условия использования и политика конфиденциальности Cointime.
Зарегистрировать аккаунт
Аккаунт уже существует?
Нажатие «page.Sign up» означает, что вы соглашаетесь с <a class="underline" href="#term-of-service">Условия использования</a> и a class="underline" href="#privacy-policy">политика конфиденциальности</a> Cointime.
Войдите, используя email
Зарегистрируйтесь с помощью email
твой почтовый ящик
Проверь свои входящие
Нажмите на ссылку в , чтобы войти.
Нажмите на ссылку в , чтобы зарегистрироваться.
Affimed
company
About
Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.
- 101 - 250
Details
- Last Funding Type
- Post-IPO Equity
- Last Funding Money Raised
- $96M
- Industries
- Biotechnology,Clinical Trials,Health Care,Medical,Therapeutics
- Founded date
- Jan 1, 2000
- Number Of Employee
- 101 - 250
- Operating Status
- Active
At Affimed, they are committed to improving outcomes for patients with cancer. Their scientific team has been devoted to unlocking the power of the innate immune system for nearly two decades to provide a unqiue approach to fighting cancer. With their unparalleled expertise in innate immunity and innate cell engager-based medicines, they aim to overcome the limitations and challenges faced by current immuno-oncology (I-O) therapies.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
3
$128M €20M
Affimed has raised a total of
$128M €20M
in funding over 2 rounds. Their latest funding was raised on
Aug 27, 2018 from a Post-IPO Equity round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Aug 27, 2018 | Post-IPO Equity | $96M | 1 |
Roche
|
— | Detail |
| Apr 29, 2010 | Series C | €20M | 1 | — | — | Detail |
| Apr 4, 2007 | Series B | $32M | 1 | — | — | Detail |
Investors
Number of Lead Investors
Number of Investors
1
3
Affimed is funded by 3 investors.
Roche
and Novo Nordisk
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
Roche
|
Yes | Post-IPO Equity |
Novo Nordisk
|
— | Series C |
|
|
— | Series B |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
